TFE3 EMSA Kit
- Known as:
- TFE3 EMSA Kit
- Catalog number:
- AY1247
- Product Quantity:
- 25 rxn
- Category:
- -
- Supplier:
- Panomics
- Gene target:
- TFE3 EMSA Kit
Related genes to: TFE3 EMSA Kit
- Gene:
- TFE3 NIH gene
- Name:
- transcription factor binding to IGHM enhancer 3
- Previous symbol:
- -
- Synonyms:
- TFEA, bHLHe33
- Chromosome:
- Xp11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1990-10-16
- Date modifiied:
- 2016-10-05
Related products to: TFE3 EMSA Kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit(1-Kit) 14,15-EET_DHET Hypertension ELISA Kit Related articles to: TFE3 EMSA Kit
- ASPSCR1::TFE3 renal cell carcinoma (RCC) is a distinct subtype of renal cell carcinoma characterized by a high rate of lymph node metastasis and poor prognosis. Its unclear pathogenesis and immune microenvironment have hindered clinical treatment. This study analyzed FFPE samples of ASPSCR1::TFE3 RCC and clear cell renal cell carcinoma (ccRCC) using single-cell sequencing and high-resolution spatial transcriptomics.The results showed significant differences in tumor and immune microenvironment between ASPSCR1::TFE3 RCC and ccRCC: ccRCC was enriched in pathways such as interferon response and hypoxia, while ASPSCR1::TFE3 RCC was involved in processes including oxidative phosphorylation and epithelial-mesenchymal transition. Tumor cells of ASPSCR1::TFE3 RCC could be divided into C3/C4 subtypes; among them, the C3 subtype, which is mainly involved in cell metastasis, showed significantly higher expression of pro-invasive genes such as MDK, MMP7, and VCAN. In terms of the immune microenvironment, ASPSCR1::TFE3 RCC exhibited an immunosuppressive phenotype, manifested by an increase in macrophages and exhausted T/NK cells. Moreover, the interaction between tumor cells and macrophages mediated by MDK-LRP1 led to its immune escape.This study confirms that ASPSCR1::TFE3 RCC is a malignant tumor with immunosuppressive features and high metastatic potential, characterized by the enrichment of the C3 subgroup and elevated MDK expression. It provides new insights for the clinical targeted therapy of ASPSCR1::TFE3 RCC and is expected to expand the population of beneficiaries of immunotherapy. - Source: PubMed
Publication date: 2026/04/18
Wang YingjingWu XiaCheng XiaoFang RongZhang PingWang HeliYu SenxiaoZhang HuizhiZhao Ming - Renal cell neoplasms with FLCN mutations, classically seen in Birt-Hogg-Dubé (BHD) syndrome typically include oncocytoma, chromophobe RCC, and hybrid oncocytic/chromophobe tumors (HOCT). Recent studies have highlighted FLCN-mutated renal cell carcinomas (RCCs) with unclassified morphologies, raising diagnostic challenges. - Source: PubMed
Publication date: 2026/04/16
Ding Chien-Kuang CChan EmilyLotan Tamara LHang Jen-FanGreenland Nancy YStohr Bradley ASimko Jeffry PSirohi Deepika - We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients. - Source: PubMed
Publication date: 2026/04/18
Chen Alice PRosenberger Christina LMoore NancyFoster Jared CNaqash Abdul RafehSharon EladO'Sullivan Coyne GeraldineSchwartz Gary KRiedel Richard FGlod JohnHu James SConley Anthony PRead William LBurgess Melissa ADavis Elizabeth JMerriam PriscillaDeshpande Hari ALadle Brian HOkuno Scott HBeck Jill CChen James LFerry-Galow Katherine VFino Kristin KMiller Brandon LWilsker Deborah FBegum AsmaParchment Ralph EDoroshow James H - TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare subtype of renal carcinoma that may present diagnostic challenges in cytologic specimens, particularly when metastatic disease represents the initial clinical manifestation. We report the case of a 72-year-old man presenting with bulky cervical lymphadenopathy clinically suspicious for lymphoma. Intraoperative touch imprint cytology from a level V lymph node demonstrated numerous discohesive and clustered epithelioid cells with abundant clear to granular cytoplasm, prompting reconsideration of a lymphoid process and appropriate tissue triage for histologic evaluation. Subsequent immunohistochemistry showed strong nuclear TFE3 expression with positivity for renal lineage markers, and RNA-based next-generation sequencing confirmed an SFPQ::TFE3 gene fusion. Imaging performed after pathologic diagnosis revealed an unsuspected renal mass. This case highlights the importance of recognizing cytomorphologic features suggestive of metastatic renal cell carcinoma during intraoperative consultation and underscores the role of cytologic evaluation in guiding diagnostic workup and tissue management in patients presenting with cervical lymphadenopathy of unknown origin. - Source: PubMed
Publication date: 2026/04/18
Pusztaszeri Marc P - - Source: PubMed
Publication date: 2026/03/18
Wang ZilinChe FengHu XuWei XinyuanZeng Hao